medigraphic.com
ISSN 1025-0255 (Electronic)

2013, Number 5

<< Back

AMC 2013; 17 (5)

Ewing´s sarcoma: review of the topic

Hernández GEH, Mosquera BG, Quintero MO, Hernández CI

Language: Spanish
References: 28
Page: 623-640
PDF size: 208.38 Kb.


ABSTRACT

Background: Ewing´s sarcoma is a highly malignant neoplasia that mainly affects children and adolescents. Around 95 % of these sarcomas appear between 525 years of age, are frequent in male sex and very infrequent in black people.
Objective: to systematize and bring up to date the most useful information about the Ewing´s sarcoma for the clinicalsurgical performance.
Method: a review of the literature from the last five years was conducted, making emphasis on epidemiology, histopathology, diagnosis, and treatment.
Development: Ewing´s sarcoma presents an incidence of 2.73 cases per million per year in the general population. From the clinical point of view the symptoms can include pseudoinflammatory problems characterized by a painful mass and pain with nighttime aggravations, along with fever, discomfort, and weight loss; these manifestations resemble an osteomyelitis. The diagnosis requires the application of immunohistochemistry techniques and molecular studies. The treatment has passed through a series of modalities: surgery, surgery and radiotherapy, radiotherapy and chemotherapy; nowadays, the surgerychemotherapy association and eventually, the radiotherapy have been taken up again.
Conclusions: histological heterogeneity favors the diversity of clinical ways of presentation and makes more complex its diagnosis. The close similarity to other diseases make of the Ewing´s sarcoma one of the tumors of most difficult treatment; that is why the early detection and the removal surgery fallowed by chemotherapy guarantee the best results.


REFERENCES

  1. Robert K. Tumores óseos malignos. En: Terry Canale S, editor. Campbell´s Operative Orthopaedics. 10ma ed. Philadelphia: Mosby; 2003. p. 83638.

  2. Fukushima M, Koizumi K, Nakajima Y, Fukuda Y, Kawamoto M, Shimizu K. Primitive Neuroectodermal Tumor/Ewing's sarcoma with Longterm Followup. The Japanese J Thor Card Sur. 2005;53(2):97101.

  3. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P. Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with InsulinLike Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures. PLoS One [Internet]. 2011 Apr [citado 15 May 2013];6(4):[aprox. 7 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071831/

  4. Shashikant SP, Gupta K, Malik V, Kumar N, Henke LE, Cal C. Primary Ewing sarcoma of cranial bones: analysis of ten patients. Acta Neurochir. 2011;153:1477–85.

  5. Kelleher FG, Thomas DM, Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/ primitive neuroectodermal tumours. Clin Sarcoma Research [Internet]. 2012 Feb [citado 15 May 2013];2(1):[aprox. 6 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351706/

  6. Ducimetiere F, Lurkin A, Ranchere Vince D, Decouvelaere AV, Peoch M, Istier L, et al. Incidence of sarcomas histotipes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLos One [Internet]. 2011 Aug [citado 15 May 2013];6(8):[aprox. 9 p.]. Disponible en: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0020294

  7. Gray ST, Chen YL, Lin DT. Efficacy of Proton Beam Therapy in the Treatment of Ewing's Sarcoma of the Paranasal Sinuses and Anterior Skull Base. Skull Base. 2009;19(6):409– 16.

  8. Lissat A, Chao MM, Konty V. Targeted therapy in Ewing sarcoma. ISRN Oncol [Internet]. 2012 May [citado 15 May 2013];2012(2012):[aprox. 9 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22690342/

  9. Van Maldegem AM, Hogendoom P, Hassan AB. The clinical use as prognostic factors in Ewing sarcoma. Clin Sarcoma Res [Internet]. 2012 Feb [citado 15 May 2013];2(7):[aprox. 10 p.]. Disponible en: http://www.clinicalsarcomaresearch.com/content/2/1/7

  10. Mandy H, Hughes D. Critical Signaling Pathways in Bone Sarcoma: Candidates for Therapeutic Interventions. Current Oncology Reports. 2009;11(6):44653.

  11. De Ávala E. Molecular pathology in sarcomas. Clin Transl Oncol. 2007;9(3):13044.

  12. Silk AW, Schuetze SM. HistologySpecific therapy for advanced soft tissue. Sarcoma and bening connective tissue tumors. Current Treatment Options in Oncology. 2012;13(3):28598.

  13. Demicco EG, Maki RG, Lev DC, Lazar AJ. New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol. 2012 May;19(3):17080.

  14. Van der Graaf WT, Gelderblom H. New systemic therapy options for advanced sarcomas. Current treat Opt Onc. 2012;13(3):30617.

  15. Ataergin S, Ozet A, Solchaga L, Turan M, Beyzadeoglu M, Oysul K, et al. Longlasting multiagent chemotherapy in adult highrisk Ewing’s sarcoma of bone. Clinical Orthopaedic and Related Research. 2010;468(10):275464.

  16. Matten FJ, Nassar A, Bardia A, Jatoi A, Haddock MG, Buckner JC, et al. Spinal intradural extraoseo Ewing sarcoma. Rare Tumors. 2011 Mar;3(1):7.

  17. Applebaum MA, Worch J, Matthay K, Goldsby R, Neuhaus J, West D, et al. Clinical features and outcomes in patients with extraeskeletal Ewing sarcoma. Cancer. 2011 Jul;117(3):3027–32.

  18. Amankwah EK, Conley AP, Reed DR. Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol [Internet] 2013 May [citado 15 May 2013];5:[aprox. 15 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660127/

  19. Enneking WF, Spanier SS, Goodman MA. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am. 1980;62(6):102730.

  20. Millan Ecalona E, Corona Pérez R, Ríos Gutiérrez N. Sarcoma de Ewing en un paciente masculino. 2010;26(3):56975.

  21. García Castellano JM, Atallah N, Healey JH, Reyes C. Histopathologic and radiologic assessmenet of chemotherapeutic response in Ewing sarcoma. A review. Sarcoma [Internet]. 2012 Feb [citado 15 May 2013];2012(2012):[aprox. 8 p.]. Disponible en: http://www.hindawi.com/journals/srcm/2012/357424/abs/

  22. Bannasch H, Eisenhardt S, Grosu A, Heinz J, Momeni A, Stark B. The diagnosis and treatment of soft tissue sarcomas of the limbs. Dtsch Arztebl Int. 2011 Jan;108(3):3238.

  23. Denbo J, Shannon W, Wu Y, Wu J, Billups C, Navid F, et al. Timing of surgery and the role of adjuvant radiotherapy in Ewing sarcoma of the chest wall: A singleinstitution experience. Ann Surg Oncol. 2012;19(12):380915.

  24. Teicher BA, Bagley R, Rouleau C, Kruger A, Ren Y, Kurtzber L. Characteristics of human Ewing /PNET sarcoma models. Ann Saudi Med. 2011 MayApr;3( 2):17482.

  25. Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, et al. The first European interdisciplinary Ewing sarcoma research summit. Front Oncol [Internet]. 2012 Apr [citado 15 May 2013];2(54):[aprox. 6 p.]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361960/

  26. Kristen N. Ganjoo. New developments in targeted therapy for soft tissue sarcoma. Curr Oncol Rep. 2010;12(4):2615.

  27. MilanoBausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani O, et al. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colonystimulating factor (GCSF) or pegylated GCSF. Clin Ther. 2009;31(2):238895.

  28. RodríguezGalindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies. Cancer. 2007;110(2):37584.




2020     |     www.medigraphic.com